Drugmakers Pfizer Inc and BioNTech SE said on May 23 that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.
https://www.pharmalive.com/wp-content/uploads/2022/05/ReutersCOVIDvaccines5-19-2022.jpg8001200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-05-23 10:50:312022-05-23 12:09:51Pfizer/BioNTech say 3 COVID shots elicit good response in children under 5